We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA.

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...

Circulating tumor cells (CTCs), originating from primary neoplastic tissues, infiltrate blood vessels, migrate through the bloodstream, and establish secondary tumor foci. The detection of CTCs holds ...

Niigata, Japan – A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University succeeded in the diagnosis of leptomeningeal disease in diffuse midline gliomas by ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.

A blood test based on whole-genome sequencing achieved 99% sensitivity and specificity for detecting HPV-positive head and neck cancer. Early postoperative detection of circulating tumor DNA predicted ...

A research team proposes a method to assess cancer patients for their likelihood to either respond to treatment or relapse. Researchers from Iwate Medical University and Tohoku University have ...